相关临床试验
43
2 进行中
药物批准
1
批准总数
监管机构
1
监管机构数
成立时间
2009
已完成
27
62.8%
尚未招募
2
4.7%
招募中
1
2.3%
终止
3
7.0%
Unknown
7
16.3%
撤回
3
7.0%
- Health Canada accepted Atabay's submission for generic acetaminophen review in August, potentially fulfilling Alberta's $49 million prepaid balance from a 2022 contract. - The original $70 million deal imported Turkish-made Parol acetaminophen and ibuprofen, but only $21 million worth was approved due to dosage and consistency issues. - Alberta Health Services discontinued Parol use after four months due to concerns about its thicker consistency and non-standard dosing in hospital settings. - The province has been exploring alternative medications since 2023, including intravenous acetaminophen, to fulfill the remaining contract obligations.
- Onco-Innovations has entered into a research agreement with the University of Alberta and Cross Cancer Institute to expand preclinical studies of its PNKP inhibitor technology for hard-to-treat cancers, beginning with glioblastoma multiforme. - The study will focus on evaluating the therapeutic potential of the company's second-generation nanoparticle formulation of PNKP inhibitors against GBM, which accounts for approximately 50% of all primary malignant brain tumors and affects over 200,000 individuals worldwide annually. - Research will be led by Dr. Michael Weinfeld, the original discoverer of the PNKP inhibitor technology, with the preclinical program scheduled to begin in the third quarter of 2025. - Key investigation areas will include pharmacological characteristics, DNA damage enhancement in tumor models, effects on normal brain tissue, and potential combination strategies with standard-of-care therapies.
- Canadian researchers have successfully developed a one-time gene therapy treatment for Fabry disease that restored enzyme production to near-normal levels in all five trial participants within one week. - The world-first trial, published in Nature Communications, used a lentivirus to deliver functional GLA genes to patients' own blood stem cells, allowing three participants to discontinue biweekly enzyme replacement therapy. - Led by Dr. Aneal Khan at Foothills Medical Centre, this pioneering approach represents a potential paradigm shift in Fabry disease management, though long-term monitoring will continue for at least five years.
